Is Zhengye Biotechnology Holding Limited (ZYBT) a Buy, Sell, or Hold?
NASDAQ : ZYBT
Zhengye Biotechnology Holding Limited
$1.8 USD
$0.42 (30.43%)
- Volume
- 15.36M
- Average Volume
- 3.44M
- Market Capitalization
- $85.3M
- P/E Ratio
- -8.18
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $13.08
- Year Low
- $0.62
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.14
Company Overview
NASDAQ
Songlin Song
Drug Manufacturers - Specialty & Generic
Healthcare
ZYBT
269
CN
USD
Liquidity Metrics
0.30
1.14
0.82
0.42
0.00
Sales & Valuation
$116.36M
7.22
2.31
14.79
0.82
Profitability
-$1.4
-$69.78M
-89.05%
-75.85%
-26.78%
-16.33%
P/E Metrics
-8.18
-0.08
-0.08
Analyst Price Target & Rating
2/5
0 Analysts
%
Financial Health Scores
No financial score data available.
Key Metrics (TTM)
$466.76M
5.83
-11.27
1.14
-26.78%
-16.15%
-16.13%
8.84%
60 days
Company Executives
| Name | Title |
|---|---|
| Aiden Han | Co-Chief Executive Officer |
| Songlin Song | Co-Chief Executive Officer |
| Ping Wang | Chief Financial Officer |
| Zhongyao Liu | Chief Operating Officer |
| Yuhong Cheng | Vice General Manager |
Poll Results
No votes yet today — be the first to share your view!
About Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) Stock
Zhengye Biotechnology Holding Limited specializes in the creation, manufacturing, and commercialization of animal health immunizations. The company primarily supplies the Chinese agricultural sector with vaccines tailored for a broad spectrum of farm animals, including swine, bovines, goats, ovines, and poultry. Additionally, its product range encompasses inoculations for canines. Beyond its domestic reach, the firm also distributes its offerings to international markets, notably exporting to Vietnam, Pakistan, and Egypt. Established in 2004, this enterprise bases its principal operations in Jilin, China, and operates as a subsidiary entity of Securingium Holding Limited. ...
Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity
2026-07-21 08:30:00
Jilin, China, July 21, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today issued the following statement in response to recent unusual trading activity in the price and trading volume of its Class A ordinary shares. The Company does not normally comment on market activity or rumors.
2026-06-04 16:05:00
Jilin, China, June 04, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, announced that the Company had received a written notification letter (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") on May 29, 2026, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules 5550(a)(2) for continued listing on the Nasdaq.
2026-06-04 16:05:00
Jilin, China, June 04, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, announced that the Company had received a written notification letter (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) on May 29, 2026, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules 5550(a)(2) for continued listing on the Nasdaq.
Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results
2026-04-28 16:30:00
JILIN, China, April 28, 2026 /PRNewswire/ -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced its financial results for the fiscal year ended December 31, 2025. Mr. Songlin Song, co-chief executive officer of Zhengye, remarked, "Fiscal year 2025 was a year of resilience for Zhengye.
Frequently Asked Questions
-
What is the current Zhengye Biotechnology Holding Limited (ZYBT) stock price?
-
Zhengye Biotechnology Holding Limited(NASDAQ:ZYBT) stock price is $1.8 in the last trading session. During the trading session, ZYBT stock reached the peak price of $13.08 while $0.616 was the lowest point it dropped to. The percentage change in ZYBT stock occurred in the recent session was 30.43% while the dollar amount for the price change in ZYBT stock was $0.42.
-
ZYBT's industry and sector of operation?
-
The NASDAQ listed ZYBT is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of ZYBT?
-
Aiden Han | Co-Chief Executive Officer
Songlin Song | Co-Chief Executive Officer
Ping Wang | Chief Financial Officer
Zhongyao Liu | Chief Operating Officer
Yuhong Cheng | Vice General Manager -
How many employees does ZYBT have?
-
Number of ZYBT employees currently stands at 269. ZYBT operates from No.1 Lianmeng Road, Jilin, JI 132101, CN.
-
Link for ZYBT official website?
-
Official Website of ZYBT is: https://www.jlzybio.com
-
How do I contact ZYBT?
-
ZYBT could be contacted at phone #86 432 6304 7008 and can also be accessed through its website. ZYBT operates from No.1 Lianmeng Road, Jilin, JI 132101, CN.
-
How many shares of ZYBT are traded daily?
-
The average number of ZYBT shares traded daily for last 3 months was 3.44M.
-
What is the market cap of ZYBT currently?
-
The market value of ZYBT currently stands at $85.3M with its latest stock price at $1.8